- Title: Subtitle
- POSTER: ABCL-370 Novel Analysis of 3-Year Results From the Pivotal EPCORE NHL-1 Study: Outcomes in Patients With Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL) and Complete Response (CR) at 2 Years With Epcoritamab Monotherapy
- Creators
- Yasmin H. Karimi - University of MichiganJulie M. Vose - University of Nebraska Medical CenterMichael Roost Clausen - Vejle SygehusDavid Cunningham - Royal Marsden NHS Foundation TrustUmar Farooq - University of IowaTatyana Feldman - Hackensack Meridian HealthHervé Ghesquieres - Hospices Civils de LyonWojciech Jurczak - The Maria Sklodowska-Curie National Research Institute of OncologyKim M. Linton - University of ManchesterTycel Phillips - U-M Rogel Cancer CenterWon Seog Kim - Samsung Medical CenterPegah Jafarinasabian - AbbVie (United States)Milan Geybels - Genmab (Denmark)David Soong - Genmab (United States)Barbara D'Angelo Månsson - Genmab (Denmark)Christian W. Eskelund - Genmab (Denmark)Mohammad Atiya - Genmab (United States)Martin Hutchings - University of CopenhagenCatherine Thieblemont - Assistance Publique – Hôpitaux de ParisChan Y. Cheah - Sir Charles Gairdner Hospital
- Resource Type
- Abstract
- Publication Details
- Clinical lymphoma, myeloma and leukemia, Vol.25(Suppl 1), pp.S254-S255
- DOI
- 10.1016/S2152-2650(25)00987-5
- ISSN
- 2152-2650
- Publisher
- Elsevier Inc
- Language
- English
- Date published
- 09/2025
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984949518502771
Abstract
POSTER: ABCL-370 Novel Analysis of 3-Year Results From the Pivotal EPCORE NHL-1 Study: Outcomes in Patients With Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL) and Complete Response (CR) at 2 Years With Epcoritamab Monotherapy
Clinical lymphoma, myeloma and leukemia, Vol.25(Suppl 1), pp.S254-S255
09/2025
DOI: 10.1016/S2152-2650(25)00987-5
Details
Metrics
6 Record Views